Trials / Recruiting
RecruitingNCT06179212
Exercise Testing Protocols for Females and Males With CAD
Comparing VO2 Peak Values of Exercise Testing Protocols for Females and Males With CAD
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 54 (estimated)
- Sponsor
- Ottawa Heart Institute Research Corporation · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is to determine if the test that allows males to achieve a higher VO2 (a measure of oxygen use during exercise) is different for females. The purpose of this study is to test 4 different exercise testing protocols to compare measured oxygen consumption in females and males with CAD (disease caused by the buildup of plaque in the artery walls which can lead to insufficient amounts of blood, nutrients and oxygen being supplied to the heart). The 4 exercise tests that will be completed on the treadmill are the modified Balke, modified Bruce, modified Naughton and University of Ottawa Heart Institute Slow Ramp protocols. Each test has a different stage duration (the amount of time that the test remains at a pre-determined speed and incline), and incremental increase in speed and incline. The main purpose of this study is to compare VO2 peak (the maximal amount of oxygen utilized during the exercise test) of females and males with CAD in 4 different exercise protocols. For example, the investigators will find out: 1. which exercise protocol is more likely to achieve a higher peak V̇O2 in females and which protocol is more likely to achieve a higher peak V̇O2 in males, 2. if enjoyment affects the duration of the test, and 3. how different exercise test protocols will provide different results of maximal oxygen used by the participant's body during the exercise test.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | Exercise Tests | Patients will complete 4 different cardiopulmonary exercise tests in random order. |
Timeline
- Start date
- 2024-03-01
- Primary completion
- 2028-12-01
- Completion
- 2030-12-01
- First posted
- 2023-12-21
- Last updated
- 2026-03-12
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT06179212. Inclusion in this directory is not an endorsement.